Ortho Dermatologics, a division of Bausch Health Companies Inc. (NYSE: BHC), today announced it has resubmitted a New Drug Application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) LotionAugust 15, 2018 1:06 PM Paulson's 13F Shows New Stakes in Akorn (AKRX), AT&T (T), Mitel (MITL), Increase in Discovery (DISCA) (More...) August 14, 2018 5:14 PM Bausch Health Companies (BHC) PT Raised to $22 at BMO CapitalAugust 13, 2018 6:38 AM